The prospective study of human application of Wenyang Huoxue Granules in adenomyosis was successfully launched together with a clinical protocol seminar in Beijing early on Aug. 26, 2023. Those attending and addressing the meeting included Mr. Li Weidong, Director of Scientific Research, and Ms. Lian Fengmei, Director of GCP Office at the project leader Guang¡¯anmen Hospital, China Academy of Chinese Medical Sciences, Mr. He Yi, vice president at the sponsor Tasly Institute. A total of about 40 people attended the seminar, including a team led by Ms. Zhao Ruihua, chief physicist at Guang¡¯anmen Hospital, the teams of PIs and leaders from 6 domestic GCP clinical trial institutions, and Tasly¡¯s project team.
Vice President He Yi, inspired by the words by Premier Li Qiang about ¡°giving full play to the distinctive Chinese medicinal, intensifying protection, and securing its development¡±, pointed out that TCM was growing with all the favorable conditions available and stressed the significance of combining clinical study with drug development. Furthermore, he showed appreciation of the generous support from the project leader and all the other organizations involved to Tasly in the development of innovative Chinese medicinal products. In addition, the vice president expressed his belief that the project, under the guidance of Prof. Zhao Ruihua and with concerted efforts by all the clinical centers, would be carried out with high efficiency and quality to quicken the process of new drug development and benefit the adenomyosis patients in the near future.
½ò¹«Íø°²±¸ 12011302120117